Company news

ALX Oncology Holdings Inc. news in 2025

ALX Oncology Holdings Inc.'s news releases, calls and decks from 2025, newest first.

View company

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

December 7, 2025

ALX Oncology to Present at Upcoming Investor Conferences

November 18, 2025

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 7, 2025

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

October 30, 2025

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

October 23, 2025

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 3, 2025

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

September 12, 2025

ALX Oncology to Participate in Upcoming Investor Conferences in September

August 29, 2025

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

August 19, 2025

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

August 5, 2025

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

May 30, 2025

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

May 20, 2025

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

May 13, 2025

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

April 25, 2025

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

April 25, 2025

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate

April 7, 2025

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 6, 2025

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

March 5, 2025

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

February 27, 2025

ALX Oncology to Host Virtual R&D Day on March 5, 2025

February 18, 2025

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

January 22, 2025

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

January 21, 2025

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

January 20, 2025

Calls in 2025

Decks in 2025